close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alloy Therapeutics

News headline image
Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
From Alloy Therapeutics
Via Business Wire
News headline image
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx™ Platform for Fully Human Antibody Discovery
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Announces Platform License Agreement with Lilly
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
From Alloy Therapeutics
Via Business Wire
News headline image
Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
From Alloy Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today